Holen Sie sich die Stockscreener-App
9.46
0.84%
-0.08
Delcath Systems Inc Aktie (DCTH) Neueste Nachrichten
Delcath Systems Announces New Data Presented at ESMO 2024 Demonstrating Efficacy of HEPZATO KIT™ in Metastatic Uveal Melanoma Subgroups - StockTitan
(DCTH) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Delcath Systems, Inc.'s (NASDAQ:DCTH) 26% Jump Shows Its Popularity With Investors - Simply Wall St
Delcath Systems (NASDAQ:DCTH) Downgraded to “Sell” at StockNews.com - Defense World
Delcath Systems (NASDAQ:DCTH) Downgraded by StockNews.com - MarketBeat
Delcath Systems Stock Gains on Positive CHEMOSAT Melanoma Data - MSN
Delcath Systems Stock Gains on Positive CHEMOSAT Melanoma Data - Yahoo Finance
Delcath Systems, Inc. (NASDAQ:DCTH) Sees Large Drop in Short Interest - MarketBeat
A US$84m Market Cap Boost Pleasing ToDelcath Systems Insiders - Yahoo Finance
Delcath Systems (STU:DV3R) Net Issuance of Preferred Stock : €0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
Delcath Systems (STU:DV3R) Total Assets : €31.51 Mil (As of Jun. 2024) - GuruFocus.com
'This Is A Very Speculative Situation,' Jim Cramer On ADMA Biologics - Benzinga
Its Stock Has Paid Off Big Time For Delcath Systems Inc - SETE News
Delcath stock jumps 15% on Hepzato Kit study publication - MSN
Delcath Systems Reveals Encouraging Uveal Melanoma Study Results - TipRanks
How to Take Advantage of moves in (DCTH) - Stock Traders Daily
Delcath Systems to Participate at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
A Guide To The Risks Of Investing In Delcath Systems Inc (DCTH) - Knox Daily
DCTH’s Stock Market Adventure: 153.37% YTD Growth Amidst Volatility - The InvestChronicle
Delcath’s Hepzato Kit offers better disease control than immunotherapy - Clinical Trials Arena
Delcath Systems stock soars to 52-week high of $9.25 By Investing.com - Investing.com Australia
Delcath study shows promise in liver cancer therapy By Investing.com - Investing.com Australia
Delcath study shows promise in liver cancer therapy - Investing.com India
Delcath Systems stock soars to 52-week high of $9.25 - Investing.com
Delcath study shows promise in liver cancer therapy By Investing.com - Investing.com Canada
Delcath Systems stock soars to 52-week high of $9.25 By Investing.com - Investing.com Canada
Delcath Systems Shares Hit 52-Week High After Tumor Study Results - MarketWatch
Delcath stock jumps 15% on Hepzato Kit study publication (NASDAQ:DCTH) - Seeking Alpha
Delcath (DCTH) Gains Market Attention After Positive Study Results - Stocks Telegraph
Delcath Systems stock soars to 52-week high of $9.25 By Investing.com - Investing.com UK
Delcath study shows promise in liver cancer therapy By Investing.com - Investing.com UK
Delcath Systems, Inc. Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma Patients - StockTitan
Is Delcath Systems (NASDAQ:DCTH) A Risky Investment? - Simply Wall St
Legato Capital Management LLC Takes $966,000 Position in Delcath Systems, Inc. (NASDAQ:DCTH) - MarketBeat
Delcath study shows promise in liver cancer treatment - Investing.com
Delcath Systems, Inc. Announces Promising Results from Independent Study on Repeated Hepatic Chemosaturation for Liver Tumors - Yahoo Finance
Delcath Systems, Inc. Announces Promising Results from Independent Study on Repeated Hepatic Chemosaturation for Liver Tumors - Business Wire
Undercovered Dozen: Delcath Systems, Bavarian Nordic, Tempus AI, Journey Energy + - Seeking Alpha
The Attractiveness of Investing In Delcath Systems Inc (DCTH) is Growing - Knox Daily
Delcath Systems Reports First Quarter 2024 Results and Business Highlights - Kilgore News Herald
Delcath Systems Announces Poster Presentation at the 2024 ESMO Congress - StockTitan
Vanguard Group Inc. Boosts Stock Position in Delcath Systems, Inc. (NASDAQ:DCTH) - MarketBeat
DCTH (Delcath Systems) Long-Term Debt & Capital Lease Obligation : $0.99 Mil (As of Jun. 2024) - GuruFocus.com
DCTH (Delcath Systems) 3-Year EBITDA Growth Rate : 29.80% (As of Jun. 2024) - GuruFocus.com
Delcath On Schedule For Monster 2025: A Platform Valuation Awaits (NASDAQ:DCTH) - Seeking Alpha
DCTH (Delcath Systems) Free Cash Flow : $-31.49 Mil (TTM As of Jun. 2024) - GuruFocus.com
Delcath Systems (NASDAQ:DCTH) Lifted to Hold at StockNews.com - MarketBeat
Delcath Systems to Host First Quarter 2024 Earnings Call - Longview News-Journal
Delcath Systems Reports First Quarter 2024 Results and Business Highlights - Longview News-Journal
Delcath Systems Inc (DCTH) may enjoy gains as insiders got busy in the recent days - Knox Daily
Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Laddcap can raise stake in Delcath to just under 20 pct - Reuters
Analysts' Revenue Estimates For Delcath Systems, Inc. (NASDAQ:DCTH) Are Surging Higher - Yahoo Finance
Delcath Systems, Inc. (DCTH) Reports Q2 Loss, Tops Revenue Estimates - MSN
Q3 2024 EPS Estimates for Delcath Systems, Inc. Boosted by HC Wainwright (NASDAQ:DCTH) - MarketBeat
Delcath Systems (NASDAQ:DCTH) Upgraded to Hold at StockNews.com - Defense World
HC Wainwright Comments on Delcath Systems, Inc.’s Q3 2024 Earnings (NASDAQ:DCTH) - Defense World
Delcath Systems (NASDAQ:DCTH) Lifted to "Hold" at StockNews.com - MarketBeat
Delcath Systems Inc (DCTH) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
Quarterly Snapshot: Quick and Current Ratios for Delcath Systems Inc (DCTH) - The Dwinnex
Delcath Systems Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Delcath Systems, Inc. (NASDAQ:DCTH) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Simply Wall St
Delcath Systems Inc (DCTH) receives a Buy rating from Craig Hallum - Knox Daily
Delcath Systems (NASDAQ:DCTH) Releases Earnings Results, Misses Estimates By $0.12 EPS - MarketBeat
Delcath Systems (NASDAQ:DCTH) Given Buy Rating at HC Wainwright - Defense World
Delcath Systems (NASDAQ:DCTH) Rating Reiterated by Stephens - MarketBeat
1.16%
0.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):